Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nuvectra Corporation
In the global pain management market, spinal cord stimulation (SCS) systems are expected to continue to be the fastest-growing segment with increasing competition among device manufacturers to develop innovative, targeted therapies. In this second article of a two-part series, we'll discuss the competitive landscape in the SCS market, the key players, emerging companies and their respective technologies.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In the $3.2 billion market for neuromodulation devices, competition is heating up in the spinal cord stimulation (SCS) segment as device manufacturers armed with new clinical trial data and next-generation technologies disrupt the status quo of standard tonic SCS systems and begin to expand the market, shift market share and boost the revenues of companies both large and small. Innovation is fueling healthy growth in this market, particularly in the US, where the market is projected to grow from around $1.13 billion in 2014 to almost $1.62 billion in 2019, a CAGR of 7.5%.
- Medical Devices
- Other Names / Subsidiaries
- Algostim, PelviStim